


ICT, Lasa realise success in Favipiravir drug synthesis

18 June 2020 | News

Favipiravir is an antiviral drug and is a promising antidote for the treatment of Coronavirus disease



Veterinary API Major, Lasa Supergenerics, and Institute of Chemical Technology had come together in the month of March 2020 in an effort to bring the antiviral to the market as a promising therapy to fight the ongoing Covid-19 pandemic.

Commenting on the development, Dr. Omkar Herlekar, Chairman– Lasa Supergenerics Limited, said Efforts over the last few months has brought success and we are looking to manufacture close to 10,000 doses, to begin with, and in the meanwhile also apply for the drug license with competent authorities and continue to seek strategic private investments or Government aid. Our move into human steroid API is in line with the organization's inherent strengths and objectives to diversify.

Commenting on the antivirals successful synthesis, Prof. Vikas N Telvekar, ICT, Mumbai, said we are happy to share with you that the Favipiravir molecule has been successfully synthesized in the ICT laboratory on a lab-scale and further pilot plan scale-up is required.”

Recently in its Q4 results, the company reported a healthy increase in its PAT to Rs 3.63 cr for FY20, as compared to a loss of Rs 12.04 cr in the corresponding period last fiscal.